Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?  Marina Noris, PhD, Piero Ruggenenti, MD, Giuseppe Remuzzi, MD, FRCP  American Journal of Kidney Diseases  Volume 70, Issue 6, Pages 754-757 (December 2017) DOI: 10.1053/j.ajkd.2017.08.005 Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Posttransplantation outcome in patients with atypical hemolytic uremic syndrome who received a kidney transplant at the Renal Transplant Unit, ASST PG23, Bergamo, Italy, from 2014 to 2017. Patients received the following treatment: pretransplantation plasma exchange (1 volume fresh frozen plasma); induction therapy: basiliximab (20mg days 0 and 4 posttransplantation) and antithymocyte globulin (0.5mg/kg/d for 1 week); and maintenance immunosuppression: steroids (1 week), cyclosporine (starting dose, 3-5mg/kg/d, then tapering), mycophenolate mofetil (750mg twice daily), or azathioprine (75mg/d). No eculizumab prophylaxis was given. Gene variant: pathogenetic or likely pathogenetic variants in complement genes. Abbreviations: CFH, complement factor H; CFI, complement factor I; MCP, membrane cofactor protein; nd, no complement gene variant detected. Data from V. Portalupi (personal communication [July 24, 2017]) and 2 of the authors (P.R. and G.R.). American Journal of Kidney Diseases 2017 70, 754-757DOI: (10.1053/j.ajkd.2017.08.005) Copyright © 2017 National Kidney Foundation, Inc. Terms and Conditions